前列腺癌根治性外照射放疗后前列腺内复发空间模式:对前列腺内优势病灶局灶加量的意义
本研究回顾性分析了根治性外照射放疗(EBRT)后经PSMA靶向探针18F-FSU-880 PET/CT检出前列腺内局部复发的12例患者,将前列腺和精囊分为14个区段,计算原发灶与复发灶的重叠率。结果显示25.0%的复发灶位于原发灶相同位置,41.7%为部分重叠,结论支持对前列腺内优势病灶进行局灶剂量提升。
要点
- 根治性EBRT后前列腺内局部复发常位于原发优势病灶相同或部分重叠的相邻部位。
- 12例患者中,复发灶与原发灶相同位置者占25.0%,部分重叠者占41.7%。
- 作者认为结果支持根治性EBRT中对前列腺内优势病灶进行局灶剂量提升。
核心结论
- 根治性EBRT后前列腺内局部复发常发生在与原发前列腺内优势病灶相同或部分重叠的相邻部位。
- 作者认为结果支持根治性EBRT中对前列腺内优势病灶进行局灶剂量提升。
研究设计与样本
- 回顾性分析来自既往2期试验的数据,该试验使用18F-FSU-880 PSMA-PET/CT评估复发前列腺癌的肿瘤检出效能。
- 纳入根治性EBRT后经PSMA-PET/CT检出前列腺内局部复发的患者12例。
- 将前列腺和精囊分为14个区段,由两名诊断放射科医生分别重新评估MRI上的原发肿瘤位置和PSMA-PET/CT上的复发肿瘤位置,计算重叠率。
主要发现
- 12例患者经PSMA-PET/CT检出局部复发,诊断局部复发的中位时间为根治性EBRT后9.1年(范围2.2-12.3年)。
- 复发肿瘤位于相同位置者占25.0%,部分重叠者占41.7%。
关键数值与推荐
- 重叠率定义为「原发肿瘤与复发肿瘤重叠的区段数」除以「复发肿瘤的总区段数」。
- 重叠率等于或大于75%时,认为复发肿瘤与原发肿瘤位于相同位置;部分重叠定义为重叠率在25%至74%之间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We retrospectively investigated spatial pattern associations between primary and recurrent tumor sites after definitive external-beam radiation therapy (EBRT) for prostate cancer, using positron emission tomography/computed tomography (PET/CT) with a prostate-specific membrane antigen (PSMA)-targeted probe, 18F-FSU-880. METHODS AND MATERIALS: We used data from our prior phase 2 trial involving patients who received PET/CT with 18F-FSU-880, which was designed to evaluate the tumor detection efficacy of PSMA-PET/CT for recurrent prostate cancer. Data from patients with local intraprostatic recurrence detected by PSMA-PET/CT after definitive EBRT were retrospectively analyzed. The prostate and seminal vesicles were divided into 14 sections. Two diagnostic radiologists separately re-evaluated the intraprostatic location of the primary tumor on magnetic-resonance imaging and that of the recurrent tumor on PSMA-PET/CT, respectively, and the rate of overlap between primary and recurrent tumors was calculated. The overlap rate was defined as "the number of sections that overlapped between the primary tumor and recurrent tumor" divided by "the total number of sections of recurrent tumor". A recurrent tumor was considered to be at the same location as the primary tumor when the overlap rate was equal to or greater than 75%, and a partial overlap was defined as an overlap rate between 25 and 74%. RESULTS: Twelve patients had local recurrence detected by PSMA-PET/CT. The median time to diagnosis of local recurrence was 9.1 (range, 2.2-12.3) years after definitive EBRT. The recurrent tumor was detected at the same location in 25.0%, and a partial overlap was noted in 41.7%. CONCLUSIONS: Local intraprostatic recurrence after definitive EBRT often occurs at the same site or at a partially overlapping site adjacent to the primary intraprostatic dominant lesion. Our results support the merit of focal dose-escalation for intraprostatic dominant lesions in definitive EBRT.
引用
- Aizawa R, Otani T, Ogata T, et al. Spatial Pattern of Intraprostatic Recurrence after Definitive External-Beam Radiation Therapy for Prostate Cancer: Implications for Focal Boost to Intraprostatic Dominant Lesion. Adv Radiat Oncol. 2024. PMID: 38681892. doi:10.1016/j.adro.2024.101489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。